InsiderDB

Lobbying disclosures · Lobbying report

TMO: second_quarter 2026 lobbying report

Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.

Follow TMO
Became public
Jul 6, 2026, 5:19 PM EDT
Event / period date
Not stated
Collected
Nov 9, 2026, 3:32 PM EST

Why this is connected

Exact legal-name match: THERMO FISHER SCIENTIFIC INC. (https://www.sec.gov/Archives/edgar/data/97745/).

Reported lobbying amounts

Income: $21,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/55016381-95d5-4ae3-94d3-606d3499068a/","filing_uuid":"55016381-95d5-4ae3-94d3-606d3499068a","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/55016381-95d5-4ae3-94d3-606d3499068a/print/","filing_document_content_type":"text/html","income":"21000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John Kevin Brennan","dt_posted":"2026-07-06T17:19:03-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"4620 Van Ness St, NW","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20016","registrant":{"id":401105447,"url":"https://lda.gov/api/v1/registrants/401105447/","house_registrant_id":null,"name":"BLUEBIRD STRATEGIES","description":"Consulting firm.","address_1":"4620 Van Ness St, NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20016","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JOHN KEVIN BRENNAN","contact_telephone":"+1 202-253-0924","dt_updated":"2026-07-07T11:45:17.907337-04:00"},"client":{"id":203728,"url":"https://lda.gov/api/v1/clients/203728/","client_id":48,"name":"THERMO FISHER SCIENTIFIC INC","general_description":"Scientific product and technology company.","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-11-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72006,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"KEVIN","last_name":"BRENNAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Price change after we could observe it

-0.07% TMO

Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Congressional trading in TMO

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.